Evidence map›Paper›PMID 36064384›Full record

SynthesisBMC cancer2022

Potential values of circulating tumor cell for detection of recurrence in patients of thyroid cancer: a diagnostic meta-analysis.

Ming-Xing Liang, Yin-Jiao Fei, Kai Yang, Wen-Juan Tang, Xin-Hui Cao, Jin-Hai Tang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ming-Xing LiangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
Yin-Jiao FeiDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
Kai YangSchool of Clinical Medicine, Xuzhou Medical University, 221000, Xuzhou, P.R. China.
Wen-Juan TangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
Xin-Hui CaoSchool of Clinical Medicine, Xuzhou Medical University, 221000, Xuzhou, P.R. China.
Jin-Hai TangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China. jhtang@njmu.edu.ORCID http://orcid.org/0000-0003-2016-4216
Jiangsu Province Hospital · CNXuzhou Medical College · CN

Funding

Jiangsu Provincial Key Research and Development Program BE2019731
6 · The paper itself

Abstract

backgroundSeveral studies have reported that circulating tumor cells (CTCs) are a promising marker for the diagnosis of thyroid cancer (TC) with recurrence or distant metastasis (DMs). However, some studies emerged with conflicting results. Therefore, we provide a meta-analysis to evaluate the diagnostic performance of CTC for detection of recurrence in patients of TC.

methodsWe searched PubMed, Web of Science, Cochrane library with the keywords "thyroid cancer" and "circulating tumor cells". Data extraction and risk of bias assessment were performed independently by two reviewers. The summary receiver operating characteristic curve (SROC) and other parameters were adopted to summarize the overall test performance. The sensitivity of CTCs in the detection of recurrent TC was reviewed. All analyses were performed by STATA 12.0 and Meta-disc software.

resultsFor CTCs expressing epithelial cell adhesion molecule (EpCAM), seven studies were included in our meta-analysis. Pooled sensitivity, specificity, and diagnostic odds ratio were 0.71 (95% CI: 0.63-0.78), 0.89 (95% CI: 0.84-0.94), and 26.75 (95% CI: 9.11-78.53); 0.78 (95% CI: 0.65-0.89), 0.88 (95% CI: 0.76-0.96), and 40.01 (95% CI: 10.49-152.63) for CTCs expressing thyroid stimulating hormone receptor (TSHR). The area under the SROC for EpCAM and TSHR were both 0.91.

conclusionCTC was a reliable marker for the diagnosis of TC patients with recurrence and DMs, and the sensitivity of CTCs expressing TSHR was higher than that of EpCAM. Additional research is warranted in order to establish uniformity in international guidelines, make up the drawbacks of conventional diagnostic methods and to prevent futile surgery.

Indexed as

Neoplastic Cells, CirculatingThyroid NeoplasmsBiomarkersEpithelial Cell Adhesion MoleculeHumansNeoplasm Recurrence, LocalBiomarkersEpithelial Cell Adhesion MoleculeCirculating tumor cellDiagnosismeta-analysisRecurrenceThyroid cancer

Identifiers

PMID36064384
PMCPMC9446830
OpenAlexW4294647569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.